Oxycodone

is prescribed to treat:

• Moderate to severe pain • Various related conditions in the pain management category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Oxycodone (OxyContin, Roxicodone, and in combination as Percocet) is a semi-synthetic opioid used for moderate to severe pain. It is effective, and its risks — respiratory depression, dependence, and overdose — are serious enough that how it is prescribed matters as much as whether it is.

Mechanism of Action

Oxycodone is a full agonist at the mu opioid receptor, with lesser activity at kappa and delta receptors. Mu receptor activation in the spinal dorsal horn reduces transmission of pain signals, and activation in the brainstem and higher centres alters the emotional and affective experience of pain — patients often describe pain still being present but mattering less.

The same receptors mediate the adverse effects, and they cannot be separated from the analgesia. Mu receptors in the brainstem respiratory centres reduce responsiveness to carbon dioxide, which is the mechanism of respiratory depression and of opioid overdose death. Mu receptors in the gut slow motility, producing constipation that — unlike sedation and nausea — does not diminish with time and must be managed for as long as the opioid continues.

Tolerance develops to analgesia, sedation, and respiratory depression, but not to constipation and not to miosis. That differential tolerance is why a patient on a stable long-term dose can lose respiratory tolerance quickly after a break in use — following hospitalisation, incarceration, or a period of abstinence — and then overdose on the dose they previously took safely. Loss of tolerance is one of the most consistent findings in opioid death investigation.

Oxycodone is metabolised primarily by CYP3A4 and partly by CYP2D6. Strong CYP3A4 inhibitors raise levels meaningfully.

Clinical Use

Opioids have a clear place in acute severe pain, post-operative pain, and cancer and palliative care. Their role in chronic non-cancer pain is far more limited than prescribing patterns of the past two decades implied — evidence for long-term benefit is weak, functional improvement is inconsistent, and harms accumulate with duration and dose.

Where an opioid is used for acute pain, the course should be short and specific. Most acute pain does not require more than a few days of treatment, and the size of the initial prescription is one of the strongest predictors of whether a patient is still taking opioids months later. Leftover tablets in home medicine cabinets are also a principal source of diversion.

Multimodal analgesia reduces opioid requirement substantially: acetaminophen and an NSAID such as ibuprofen together provide analgesia comparable to an opioid for many acute conditions, and combining them with an opioid allows a lower dose. For neuropathic pain, gabapentin, pregabalin, or duloxetine are more appropriate than opioids. The managing chronic pain without opioids article covers the broader approach.

Combination products containing acetaminophen, such as hydrocodone-acetaminophen and oxycodone-acetaminophen, carry a hepatotoxicity ceiling that limits how far the opioid component can be escalated and creates overdose risk if a patient also takes over-the-counter acetaminophen.

Safety and Naloxone

Concurrent benzodiazepine use is the single most important modifiable risk factor for opioid overdose death, and the FDA carries a boxed warning about the combination. Where both are genuinely necessary, doses of each should be lower and the risk discussed explicitly.

Naloxone should be co-prescribed for patients on higher doses, those taking benzodiazepines concurrently, those with respiratory disease or substance use history, and anyone with a household member at risk. It is an opioid antagonist that reverses respiratory depression, it is available as a nasal spray requiring no training, and household members should know where it is and how to use it. Offering it is not an accusation, and framing it as standard practice — like a fire extinguisher — makes it easier to accept. The CDC opioid prescribing resource sets out current guidance.

Constipation should be anticipated from the first dose rather than treated once established. A stimulant laxative such as senna, with or without a stool softener, is standard, and polyethylene glycol is a reasonable addition. Fibre alone is inadequate and can worsen matters.

Monitoring and Follow-Up

Prescription drug monitoring program review is appropriate at initiation and periodically. Assessment should cover pain, function, adverse effects, and any signs of problematic use — function matters more than pain scores, since an opioid that reduces pain without improving what a patient can do is not achieving its purpose.

Urine drug testing is used in longer-term therapy. Written treatment agreements set expectations. Neither is a substitute for the ongoing clinical relationship in which these decisions are actually made.

Opioids should not be stopped abruptly after prolonged use. Withdrawal is deeply unpleasant though not usually dangerous, and abrupt discontinuation drives patients toward illicit sources — a well-documented harm of well-intentioned tapering. Tapers should be gradual and collaborative. The MedlinePlus oxycodone entry covers prescribing detail.

Special Populations

In older adults, opioids increase falls, fractures, confusion, and constipation, and clearance is reduced; start low and titrate slowly. In kidney and hepatic impairment, accumulation occurs and doses should be reduced.

In pregnancy, opioid use can cause neonatal opioid withdrawal syndrome, and it is used only when clearly needed. Patients with opioid use disorder require buprenorphine or methadone rather than escalating full-agonist therapy, and that is a treatable condition with effective medication rather than a reason for discharge from care. Sleep apnea and respiratory disease raise respiratory depression risk substantially.

When to Contact Your Doctor

Seek emergency care immediately for slow or difficult breathing, extreme sleepiness, unresponsiveness, or blue-tinged lips or fingertips — and use naloxone if available. These signs, particularly with alcohol, benzodiazepines, or sedatives, indicate overdose.

Report constipation, which should be treated rather than tolerated. Report sedation that interferes with function, and do not drive until you know how the drug affects you. Report if the dose is no longer controlling pain, if you are taking more than prescribed, or if you find yourself thinking about the medication a great deal — these are treatable situations and raising them early leads to better outcomes than concealing them.

To review your pain management, discuss reducing or stopping an opioid safely, or explore alternatives, contact us or schedule a visit.